Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Current Deferred Revenue: 2011-2022

Historic Current Deferred Revenue for Myriad Genetics (MYGN) over the last 12 years, with Sep 2022 value amounting to $200,000.

  • Myriad Genetics' Current Deferred Revenue fell 98.26% to $200,000 in Q3 2022 from the same period last year, while for Sep 2022 it was $200,000, marking a year-over-year decrease of 98.26%. This contributed to the annual value of $5.2 million for FY2021, which is 84.10% down from last year.
  • Per Myriad Genetics' latest filing, its Current Deferred Revenue stood at $200,000 for Q3 2022, which was down 33.33% from $300,000 recorded in Q2 2022.
  • Over the past 5 years, Myriad Genetics' Current Deferred Revenue peaked at $32.8 million during Q2 2020, and registered a low of $200,000 during Q3 2022.
  • For the 3-year period, Myriad Genetics' Current Deferred Revenue averaged around $15.7 million, with its median value being $11.5 million (2021).
  • As far as peak fluctuations go, Myriad Genetics' Current Deferred Revenue soared by 1,438.10% in 2020, and later plummeted by 98.67% in 2022.
  • Over the past 5 years, Myriad Genetics' Current Deferred Revenue (Quarterly) stood at $2.4 million in 2018, then spiked by 50.00% to $3.6 million in 2019, then surged by 808.33% to $32.7 million in 2020, then crashed by 84.10% to $5.2 million in 2021, then plummeted by 98.26% to $200,000 in 2022.
  • Its Current Deferred Revenue stands at $200,000 for Q3 2022, versus $300,000 for Q2 2022 and $700,000 for Q1 2022.